Stock Markets July 30, 2026 06:59 AM

Bristol Myers Lifts 2026 Profit Outlook as Eliquis, Newer Treatments Drive Strong Q2

Quarterly results outpace estimates as growth drugs offset declines from older brands

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
BMY

Bristol Myers Squibb reported second-quarter revenue and adjusted earnings that beat analyst expectations, prompting the company to raise its full-year revenue guidance and increase its 2026 adjusted earnings forecast. Powerful sales of the blood thinner Eliquis and several recently launched medicines - including Camzyos, Reblozyl and Breyanzi - underpinned results, while older products facing generic competition continued to weigh on revenue.

Bristol Myers Lifts 2026 Profit Outlook as Eliquis, Newer Treatments Drive Strong Q2
BMY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Bristol Myers reported Q2 revenue of $12.97 billion and adjusted EPS of $2.04, both above analyst expectations - impacting the pharmaceuticals and healthcare sectors.
  • The company raised full-year revenue guidance to $49 billion-$50 billion and increased its adjusted 2026 earnings forecast to $6.75-$7.00 per share - relevant to equity markets and investors in healthcare stocks.
  • Growth was concentrated in Eliquis and newer medicines (Reblozyl, Camzyos, Breyanzi), as the company offsets declines in older drugs facing generic competition - affecting biotech and specialty therapeutics segments.

Bristol Myers Squibb reported a stronger-than-expected second quarter, led by robust demand for its blood thinner Eliquis and several newer products, and has raised both its full-year revenue outlook and its adjusted earnings projection for 2026.

For the quarter, the U.S. drugmaker recorded revenue of $12.97 billion, an increase of 6% from the same period a year earlier and above the LSEG analysts' average estimate of $11.75 billion. The company posted adjusted earnings of $2.04 per share, topping expectations of $1.59 per share.

Following the results, Bristol Myers raised its full-year revenue guidance to a range of $49 billion to $50 billion, up from its prior forecast of $46 billion to $47.5 billion. It also increased its adjusted earnings outlook for 2026 to $6.75 to $7.00 per share from an earlier $6.05 to $6.35 range.


Performance by franchise

Eliquis, the partnered anticoagulant that Bristol Myers markets jointly with Pfizer, was a major contributor to the quarter. Eliquis sales reached $4.48 billion, a 22% rise and above analysts' estimates of $4.06 billion. Management has lifted the Eliquis sales growth forecast for the year to a 20% to 25% increase, up from a prior projection of 10% to 15%.

Company executives noted that Eliquis' share of new U.S. prescriptions is approaching 80%. Bristol Myers had previously raised this forecast in February, saying a price reduction would allow it to avoid penalties under the U.S. Medicare program.

Newer medicines also outperformed expectations. Reblozyl, an anemia therapy, generated $735 million in sales versus analyst expectations of about $664 million. Camzyos, a heart medicine, delivered $416 million compared with expected sales of $365 million. The cancer cell therapy Breyanzi produced $484 million, topping estimates of $422 million.

Opdivo, the company’s established cancer immunotherapy, saw sales decline 3% to $2.49 billion, slightly below Wall Street expectations. Management is focused on converting patients from intravenous Opdivo to a subcutaneous formulation called Qvantig. Conversion from the intravenous form is approaching 15%.

Qvantig added $261 million in quarterly revenue, exceeding analysts’ estimates of $215 million. Bristol Myers said combined sales of Opdivo and Qvantig are growing at a mid-single-digit rate.


Portfolio dynamics and pressures

The company continues to contend with sales erosion in older brands facing generic competition. Revlimid, once Bristol Myers’ top-selling drug, saw sales fall 49% to $425 million in the quarter. Management highlighted that its growth portfolio expanded 15% in Q2 and that nine products are posting double-digit growth; these medicines are described as early in their commercial life cycles.

Management commentary emphasized the company's strategy of offsetting declines from legacy products with newer launches and growth-stage assets.


Implications for markets and stakeholders

The stronger top-line performance and upward revision to guidance underscore the commercial momentum behind Eliquis and a slate of recently introduced therapies, while continuing generic pressure on older oncology medicines represents a headwind. Investors will likely watch Eliquis prescription trends, the pace of conversion to Qvantig, and the durability of launches such as Reblozyl and Camzyos as drivers of future results.

Risks

  • Ongoing generic competition for legacy drugs such as Revlimid continues to reduce sales in the oncology portfolio, posing downside risk to overall revenue - affects oncology drugmakers and biotech investors.
  • Conversion rates from established therapies to newer formulations (for example, intravenous Opdivo to subcutaneous Qvantig) remain below full penetration, creating execution risk for growth ambitions - impacts commercial performance in oncology therapeutics.
  • Dependence on Eliquis growth and prescription share increases to sustain top-line momentum exposes the company to regulatory or pricing pressures, including mechanisms tied to the U.S. Medicare program - relevant to payers and pharmaceutical pricing dynamics.

More from Stock Markets

Ferrari CEO Says Luce Orders Meet Expectations Despite Mixed Early Reviews Jul 30, 2026 Activist Jana Demands Full Portfolio Review and Board Refresh at Fiserv Jul 30, 2026 Analysts Trim Ratings on Fiverr as AI-Related Headwinds Intensify Jul 30, 2026 Belden Shares Spike After Second-Quarter Beat, Management Raises Near-Term Revenue Outlook Jul 30, 2026 Atoms’ $1.7 Billion Raise and Uber’s Stake Elevate Competitive Risks for DoorDash Jul 30, 2026